Understanding the impact of RSV infection in older adults in primary care in the Netherlands
RSV Burden in Older Adults in Primary Care in The Netherlands: the RAPID Study
This study is trying to understand how Respiratory Syncytial Virus (RSV) affects older adults in the Netherlands by looking at their symptoms and healthcare needs when they have respiratory issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | UMC Utrecht Academic / other |
| Locations | 1 site (Utrecht) |
| Trial ID | NCT06318936 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the burden of Respiratory Syncytial Virus (RSV) infection among older adults in Dutch primary care settings. By utilizing rapid molecular viral diagnostic testing, the study will identify RSV-positive cases among patients presenting with acute respiratory symptoms. Participants will complete questionnaires at multiple time points to gather data on clinical symptoms, healthcare utilization, and quality of life. The findings will help quantify the impact of RSV in this population and inform future vaccination strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are older adults aged 60 years and above who present with acute respiratory symptoms and test positive for RSV.
Not a fit: Patients who do not have RSV infection or are unable to communicate in the local language or English may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the burden of RSV in older adults, aiding in the implementation of effective vaccination programs.
How similar studies have performed: While the burden of RSV in older adults has been studied, this specific observational approach in primary care settings is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age (≥60 years of age) * RSV positive * Subject is willing and able to give informed consent for participation in the study * Subject is willing and able to adhere to protocol-specific procedures Exclusion Criteria: * Subject is not able to understand and communicate in the local language or English. * Previous or current participation in RSV interventional trial (vaccine, antivirals)
Where this trial is running
Utrecht
- University Medical Center Utrecht — Utrecht, Netherlands (Recruiting)
Study contacts
- Principal investigator: Louis Bont, MD, PhD — UMC Utrecht
- Study coordinator: Joanne G Wildenbeest, MD, PhD
- Email: J.G.Wildenbeest@umcutrecht.nl
- Phone: 0031887563776
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.